Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
13 stopped studies mapped to Thyroid Gland Anaplastic Carcinoma and descendants · 85% state a reason
Over the 13 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Phase 1 | suspended | Sep 18, 2025 | Chongqing Precision Biotech Co., Ltd | Sponsor stopped the study. | Other (stated, no rule matched) |
| NCT05453799 | Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer… | Phase 2 | suspended | Jul 12, 2022 | Northwestern University | Per sponsor letter, due to a business decision based on reprioritization of their internal… | Enrollment / accrual |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid… | Phase 2 | withdrawn | Feb 1, 2021 | Saint Petersburg State University, Russia | Lack of funding | Funding |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive…(ANAPLAST-NEO) | Phase 2 | withdrawn | Feb 4, 2021 | Saint Petersburg State University, Russia | Lack of funding | Funding |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | Phase 1 / Phase 2 | terminated | Jan 29, 2008 | Daiichi Sankyo | Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated… | Safety / toxicity |
| NCT02657369 | A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | Phase 2 | terminated | Jan 15, 2016 | Eisai Inc. | Overall response rate was 3% (only 1 out of 33 participants had confirmed PR). | Other (stated, no rule matched) |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | Phase 2 | withdrawn | Nov 13, 2014 | University of Texas Southwestern Medical Center | study was on hold for protocol redesign; decided to not move forward with study. | Other (stated, no rule matched) |
| NCT00126568 | Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer | Phase 2 | terminated | Aug 4, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02516774 | A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With…(TAM-RT) | Phase 1 | withdrawn | Aug 6, 2015 | Gustave Roussy, Cancer Campus, Grand Paris | No patients enrolled | Enrollment / accrual |
| NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid…(FACT) | Phase 2 / Phase 3 | terminated | Jul 26, 2007 | Mateon Therapeutics | Low rate of subject accrual | Enrollment / accrual |
| NCT01701349 | Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid…(FACT2) | Phase 3 | withdrawn | Oct 5, 2012 | Mateon Therapeutics | Expected inability to recruit study participants in a reasonable amount of time. | Enrollment / accrual |
| NCT00095693 | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally… | Phase 2 | terminated | Nov 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials